FDA-Biopharm Relationship Improving But Needs Work

Communications between the FDA and the biopharmaceutical/medical device industry have significantly improved, but the relationship is still strained by unnecessary approval
delays, according to a survey by the University of California at San Diego and PricewaterhouseCoo-pers. The study, first conducted in 1995, tracks the non-science-based factors
that delay the FDA approval process. Survey respondents were U.S. companies that had a drug device or biologic in clinical trials under the FDA's supervision between Jan. 1, 1998
and June 30, 1999.